Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.

MLA

Perdomo-Pantoja, Alexander, et al. “Angiotensinogen Rs5050 Germline Genetic Variant as Potential Biomarker of Poor Prognosis in Astrocytoma.” PloS One, vol. 13, no. 11, Nov. 2018, p. e0206590. EBSCOhost, https://doi.org/10.1371/journal.pone.0206590.

APA

Perdomo-Pantoja, A., Mejía-Pérez, S. I., Reynoso-Noverón, N., Gómez-Flores-Ramos, L., Soto-Reyes, E., Sánchez-Correa, T. E., Guerra-Calderas, L., Castro-Hernandez, C., Vidal-Millán, S., Sánchez-Corona, J., Taja-Chayeb, L., Gutiérrez, O., Cacho-Diaz, B., Alvarez-Gomez, R. M., Gómez-Amador, J. L., Ostrosky-Wegman, P., Corona, T., Herrera-Montalvo, L. A., & Wegman-Ostrosky, T. (2018). Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma. PloS One, 13(11), e0206590. https://doi.org/10.1371/journal.pone.0206590

Chicago

Perdomo-Pantoja, Alexander, Sonia Iliana Mejía-Pérez, Nancy Reynoso-Noverón, Liliana Gómez-Flores-Ramos, Ernesto Soto-Reyes, Thalía Estefania Sánchez-Correa, Lissania Guerra-Calderas, et al. 2018. “Angiotensinogen Rs5050 Germline Genetic Variant as Potential Biomarker of Poor Prognosis in Astrocytoma.” PloS One 13 (11): e0206590. doi:10.1371/journal.pone.0206590.